本文選題：骨化三醇 + 西那卡塞��； 參考：《海南醫(yī)學(xué)院學(xué)報(bào)》2016年24期

【摘要】：目的:探討骨化三醇、西那卡塞聯(lián)合護(hù)理干預(yù)對(duì)維持性血液透析(MHD)患者繼發(fā)性甲狀旁腺功能亢進(jìn)(SHPT)血清成纖維細(xì)胞生長(zhǎng)因子23(FGF23)的影響。方法:選取我院收治的SHPT患者90例為研究對(duì)象,隨機(jī)分為觀察組和對(duì)照組。兩組均給予護(hù)理干預(yù),于進(jìn)食時(shí)吞服鹽酸西那卡塞,開始劑量為25mg/d,每2~4周根據(jù)全段甲狀旁腺激素(iPTH)、鈣(Ca)、磷(P)水平調(diào)整劑量,最大劑量不超過75mg/d,觀察組在上述治療基礎(chǔ)上口服骨化三醇膠丸0.25μg/d,3次/周,兩組均治療3個(gè)月后進(jìn)行效果評(píng)價(jià)。兩組治療前后采集清晨空腹外周靜脈血,采用比色法測(cè)定Ca、P,ELISA法測(cè)定iPTH及血清FGF23、骨特異性堿性磷酸酶(BSAP),全自動(dòng)生化檢測(cè)儀測(cè)定血肌酐(Scr)、尿毒氮(BUN),單室尿素動(dòng)力學(xué)模型進(jìn)行量化分析檢測(cè)尿素清除指數(shù)(KT/V)。結(jié)果:觀察組治療后Ca升高程度,P、iPTH降低程度大于對(duì)照組(P0.05),兩組治療后BUN、Scr、KT/V無(wú)明顯變化(P0.05),觀察組治療后FGF23、BSAP水平降低程度大于對(duì)照組(P0.05)。結(jié)論:骨化三醇、西那卡塞聯(lián)合護(hù)理干預(yù)治療MHD患者SHPT,可有效降低PTH、FGF23、BSAP水平,改善臨床癥狀。
[Abstract]:Objective: to investigate the effect of ossifying triol and combined nursing intervention with Sinakaser on serum fibroblast growth factor 23 FGF23 in secondary hyperparathyroidism parathyroid hyperparathyroidism (SHPTT) patients with maintenance hemodialysis (HD). Methods: 90 patients with SHPT were randomly divided into observation group and control group. The two groups were given nursing intervention. The initial dose was 25mg / d. The dose was adjusted every 2 weeks according to the levels of the whole level of parathyroid hormone iPTHG, calcium, phosphoric acid. The maximum dose was not more than 75 mg / d. The observation group took 0.25 渭 g / d of oscitic triol colloidal pill three times a week on the basis of the above treatment. The effect was evaluated after 3 months of treatment in both groups. Fasting peripheral venous blood was collected before and after treatment in both groups. IPTH and serum FGF23 were determined by colorimetric method, bone specific alkaline phosphatase (BSAP), serum creatinine (creatinine), urinary nitrogen bun, urea clearance index (KT / V) were determined by single chamber urea kinetic model. Results: the degree of Ca increase in the observation group was higher than that in the control group (P 0.05), but there was no significant change in KT / V between the two groups after treatment. The decrease of the level of FGF23 / BSAP in the observation group was higher than that in the control group (P 0.05). Conclusion: combined nursing intervention of ossifying triol and Sinakaser can effectively reduce the level of FGF23 BSAP and improve clinical symptoms in patients with MHD.
【作者單位】： 河北北方學(xué)院附屬第二醫(yī)院五官科病房;河北北方學(xué)院附屬第二醫(yī)院腎內(nèi)科;
【基金】：張家口市科學(xué)技術(shù)和地震局計(jì)劃項(xiàng)目(1521095D)~~
【分類號(hào)】：R473.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 繆立英;金麗娜;沈建琴;朱濱;;西那卡塞對(duì)維持性血液透析繼發(fā)甲狀旁腺功能亢進(jìn)患者血清FGF-23的影響[J];江蘇醫(yī)藥;2016年13期

2 馮希偉;;活性維生素D及磷結(jié)合劑加用鹽酸西那卡塞治療慢性腎衰竭透析患者繼發(fā)甲狀旁腺功能亢進(jìn)的臨床療效[J];臨床合理用藥雜志;2016年06期

3 王U，

本文編號(hào)：1933106